Encouraging results have been shown for relapsed childhood B-ALL [107], as also reported by a recent phase I clinical trial combining Everolimus (an allosteric mTOR inhibitor) with conventional chemotherapeutic drugs (NCT01523977). The gene discussed is MTOR; the disease is precursor B-cell acute lymphoblastic leukemia.